Clinical Trial Update: Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) [Phase 2]

View source ↗

Summary

A Phase 2 trial update reporting efficacy, safety and tolerability of DNK333 (25 mg twice daily) in women with diarrhea-predominant irritable bowel syndrome (IB…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• DNK333

Snippet

Sponsor: Novartis | Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D) | Phase 2 | Status: COMPLETED